Smith & Nephew PLC (LSE:SN) drew a cautious assessment from Jefferies on Friday, with the broker maintaining its 'buy' rating despite investor scepticism over execution and a reduced financial year 2026 guidance.
Shares in the company traded around 1,059p as Jefferies held its 1,500p price target, citing an all-time low valuation of 12 times estimated 2027 earnings alongside lumpy operational execution.
At the heart of the update is investor scepticism about delivering 5.0%-5.5% organic sales growth in the second half, following 2.3% in the first half.
That acceleration is needed to meet a lower 4% financial year target, down from 6% previously, with market consensus already pricing in a miss of 3.6%.
Adding to investor anxiety, the unexpected departure of the chief financial officer has created an unwelcome distraction, with Jefferies noting that Baxter's offer was 'difficult to ignore'.
Regulatory headwinds include CMS reimbursement and billing changes affecting skin substitutes, as well as WISeR-related claims friction, which have slowed utilisation.
Smith & Nephew now expects the impact to reach the upper end of a $20 million to $40 million headwind to trading profit.
Alongside China's volume-based procurement programme in AET and ENT, Jefferies views the group as a relative safe haven, although tariffs will weigh by about $60 million given 2026 refunds.
With activist shareholder Cevian holding above 14%, Jefferies noted all portfolio options remain on the table, including a potential orthopaedics sale or spin-off, with the board considering potential dis-synergies with Sports Medicine and tax implications.
A key early-2027 catalyst is MediWound's expected phase III VALUE-trial readout for EscharEx, which Jefferies said could put pressure on Santyl.
Santyl has approximately $400 million in sales and around 80% market share, while Smith & Nephew points to its 60-year clinical record and logistical drawbacks for EscharEx, including cold-chain requirements and nurse application.
